1. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation.
- Author
-
Swietlik JJ, Bärthel S, Falcomatà C, Fink D, Sinha A, Cheng J, Ebner S, Landgraf P, Dieterich DC, Daub H, Saur D, and Meissner F
- Subjects
- Animals, Mice, Proteomics, Proteome metabolism, Biomarkers, Tumor metabolism, Gene Expression Regulation, Neoplastic, Pancreatic Neoplasms, Pancreatic Neoplasms metabolism, Carcinoma, Pancreatic Ductal pathology
- Abstract
Cell-selective proteomics is a powerful emerging concept to study heterocellular processes in tissues. However, its high potential to identify non-cell-autonomous disease mechanisms and biomarkers has been hindered by low proteome coverage. Here, we address this limitation and devise a comprehensive azidonorleucine labeling, click chemistry enrichment, and mass spectrometry-based proteomics and secretomics strategy to dissect aberrant signals in pancreatic ductal adenocarcinoma (PDAC). Our in-depth co-culture and in vivo analyses cover more than 10,000 cancer cell-derived proteins and reveal systematic differences between molecular PDAC subtypes. Secreted proteins, such as chemokines and EMT-promoting matrisome proteins, associated with distinct macrophage polarization and tumor stromal composition, differentiate classical and mesenchymal PDAC. Intriguingly, more than 1,600 cancer cell-derived proteins including cytokines and pre-metastatic niche formation-associated factors in mouse serum reflect tumor activity in circulation. Our findings highlight how cell-selective proteomics can accelerate the discovery of diagnostic markers and therapeutic targets in cancer., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF